ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 984,93
-0,99%
Dow Jones
37 815,92
-1,49%
DAX
17 932,17
-1,10%
Brent Oil
85,585
-0,36%
Bitcoin
60 048,51
-0,91%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Royalty Pharma PLC (RPRX)

  7. Royalty Pharma PLC (RPRX) Actualités

RPRX Royalty Pharma PLC

27,70
-0,42 (-1,49%)
01 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Royalty Pharma PLC RPRX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,42 -1,49% 27,70 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
28,05 27,68 28,13 27,70 28,12
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
19/4/202414:15GLOBERoyalty Pharma to Announce First Quarter 2024 Financial..
17/4/202414:15GLOBERoyalty Pharma Declares Second Quarter 2024 Dividend
28/2/202422:15GLOBERoyalty Pharma to Present at TD Cowen’s 44th Annual Health..
15/2/202415:05EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
15/2/202413:33EDGAR2Form 8-K - Current report
15/2/202413:30GLOBERoyalty Pharma Reports Q4 and Full Year 2023 Results
06/2/202413:01EDGAR2Form 8-K - Current report
30/1/202422:15GLOBERoyalty Pharma To Announce Fourth Quarter And Full Year 2023..
19/1/202414:15GLOBERoyalty Pharma Announces Dividend Increase
08/1/202413:18EDGAR2Form 8-K - Current report
08/1/202413:00GLOBERoyalty Pharma Highlights Accomplishments and Provides..
03/1/202422:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202422:30EDGAR2Form 144 - Report of proposed sale of securities
29/12/202322:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202322:31EDGAR2Form 8-K - Current report
27/12/202319:05EDGAR2Form 8-K - Current report
19/12/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202322:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202322:47EDGAR2Form 144 - Report of proposed sale of securities
27/11/202322:15GLOBERoyalty Pharma to Present at the Evercore ISI 6th Annual..
16/11/202323:16EDGAR2Form 8-K - Current report
16/11/202323:13EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
15/11/202301:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202314:10GLOBERoyalty Pharma and Teva Collaborate to Further Accelerate..
13/11/202314:00BWTeva and Royalty Pharma Collaborate to Further Accelerate..
08/11/202315:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202313:40EDGAR2Form 8-K - Current report
08/11/202313:00GLOBERoyalty Pharma Reports Third Quarter 2023 Results
19/10/202315:29EDGAR2Form 8-K - Current report
19/10/202313:59GLOBERoyalty Pharma Announces Agreement to Purchase Up to $1.5..
16/10/202322:15GLOBERoyalty Pharma Declares Fourth Quarter 2023 Dividend
11/10/202322:15GLOBERoyalty Pharma To Announce Third Quarter 2023 Financial..
03/10/202322:15EDGAR2Form 144 - Report of proposed sale of securities
03/10/202322:15EDGAR2Form 144 - Report of proposed sale of securities
21/9/202314:25GLOBERoyalty Pharma Appoints Eric Schneider as Chief Technology..
05/9/202322:15GLOBERoyalty Pharma and Ascendis Pharma Enter Into $150 Million..
05/9/202322:01GLOBEAscendis Pharma and Royalty Pharma Enter into $150 Million..
05/9/202314:25GLOBERoyalty Pharma to Present at Upcoming Investor Conferences
24/8/202312:30GLOBERoyalty Pharma and Ferring Pharmaceuticals Enter Into US..
24/8/202307:15BWRoyalty Pharma and Ferring Pharmaceuticals Enter into US..
11/8/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202322:45EDGAR2Form 144 - Report of proposed sale of securities
08/8/202323:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202323:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202315:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202313:31EDGAR2Form 8-K - Current report
08/8/202313:00GLOBERoyalty Pharma Reports Second Quarter 2023 Results
18/7/202322:15GLOBERoyalty Pharma to Announce Second Quarter 2023 Financial..
17/7/202322:15GLOBERoyalty Pharma Declares Third Quarter 2023 Dividend
15/7/202300:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Dernières Valeurs Consultées

NASDAQ
RPRX
Royalty Pharma
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés